Vantictumab - OncoMed Pharmaceuticals
Alternative Names: Anti-frizzled receptor monoclonal antibody - OncoMed; Anti-Fzd receptor monoclonal antibody - OncoMed; anti-Fzd7; Anti-Fzd7 receptor monoclonal antibody - OncoMed; OMP-18R5; VantictumabLatest Information Update: 01 Aug 2024
At a glance
- Originator Bayer HealthCare Pharmaceuticals; OncoMed Pharmaceuticals
- Developer OncoMed Pharmaceuticals
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Frizzled receptor antagonists; Stem cell inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Breast cancer; Non-small cell lung cancer; Pancreatic cancer
Highest Development Phases
- No development reported HER2 negative breast cancer; Non-small cell lung cancer; Pancreatic cancer
Most Recent Events
- 28 Jun 2020 No recent reports of development identified for phase-I development in Breast-cancer(Combination therapy, Late-stage disease) in USA (IV, Infusion)
- 28 Jun 2020 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Combination therapy, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in USA (IV, Infusion)
- 28 Jun 2020 No recent reports of development identified for phase-I development in Pancreatic-cancer(Combination therapy, First-line therapy, Late-stage disease) in USA (IV, Infusion)